The Oncology Institute, Inc. Reports Q1 Loss, Lags Revenue Estimates
The Oncology Institute, Inc. (NASDAQ: TOI) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -83.33%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced a loss of $0.21, delivering a surprise of -90.91%.
Over the last four quarters, the company has not been able to surpass consensus EPS estimates.
The Oncology Institute, which belongs to the Zacks Medical Services industry, posted revenues of $94.67 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 0.53%. This compares to year-ago revenues of $76.19 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary …
Full story available on Benzinga.com
